ArticleScientific reports2021
Characterization of Bacillus velezensis AK-0 as a biocontrol agent against apple bitter rot caused by Colletotrichum gloeosporioides.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 85 citations in OpenAlex.
- Enhanced Control of Pepper Anthracnose through Co-Application of Paenibacillus polymyxa GYUN-2285 and Pseudomonas protegens GYUN-2679.The plant pathology journal · 2026Article
- Plant-soil-microbiome interactions: mechanisms, advances, and challenges in sustainable agriculture and healthy agroecosystems.Frontiers in microbiology · 2026Review
- Isolation and Genome-Based Characterization ofMicroorganisms · 2025Article
- Acid-resistantApplied and environmental microbiology · 2025Article
- Cellulolytic Potential of Newly Isolated Alcohol-TolerantMaterials (Basel, Switzerland) · 2025Article
- Probiotic potential of Bacillus velezensis STPB10 sourced from the gut microbiota of a hillstream fish Schizothorax richardsonii (Gray, 1832) for aquaculture applications.Scientific reports · 2025Article
- A three-way transcriptomic crosstalk interaction in a biocontrol agent (Bacillus velezensis), a fungal pathogen (Colletotrichum gloeosporioides), and a walnut host (Juglans regia L.).BMC plant biology · 2025Article
- In vitro and In silico investigation deciphering novel antifungal activity of endophyte Bacillus velezensis CBMB205 against Fusarium oxysporum.Scientific reports · 2025Article
- Characterization and Biocontrol Efficacy of Bacillus velezensis GYUN-1190 against Apple Bitter Rot.The plant pathology journal · 2024Article
- Isolation of Heavy Metal-Tolerant and Anti-Phytopathogenic Plant Growth-Promoting Bacteria from Soils.Journal of microbiology and biotechnology · 2024Article
- Computational approach to identify novel genomic features conferring high fitness in Bacillus atrophaeus CNY01 and Bacillus velezensis AK-0 associated with plant growth promotion (PGP) in apple.BMC plant biology · 2024Article
- Genome Sequencing and Characterization ofMicroorganisms · 2024Article
- Antifungal Effect ofInternational journal of molecular sciences · 2023Article
- Management of sunflower charcoal-rot and maize late-wilt diseases using the aqueous extract of vermicompost (vermitea) and environmental-safe biochar derivative (wood vinegar).Scientific reports · 2023Article
- Diversity and Biocontrol Potential of Endophytic Fungi and Bacteria Associated with Healthy Welsh Onion Leaves in Taiwan.Microorganisms · 2023Article
- Biocontrol Potential of Some Rhizospheric Soil Bacterial Strains againstMicroorganisms · 2023Article
- Ferric Chloride Controls Citrus Anthracnose by Inducing the Autophagy Activity ofJournal of fungi (Basel, Switzerland) · 2023Article
- Reviewing and renewing the use of beneficial root and soil bacteria for plant growth and sustainability in nutrient-poor, arid soils.Frontiers in plant science · 2023Review
- Screening and characterization of biocontrol bacteria isolated fromFrontiers in microbiology · 2023Article
- Evaluation ofFrontiers in plant science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacillus genus produces several secondary metabolites with biocontrol ability against various phytopathogens. Bacillus velezensis AK-0 (AK-0), an antagonistic strain isolated from Korean ginseng rhizospheric soil, was found to exhibit antagonistic activity against several phytopathogens. To further display the genetic mechanism of the biocontrol traits of AK-0, we report the complete genome sequence of AK-0 and compared it with complete genome sequences of closely related strains. We report the biocontrol activity of AK-0 against apple bitter rot caused by Colletotrichum gloeosporioides, which could lead to commercialization of this strain as a microbial biopesticide in Korea. To retain its biocontrol efficacy for a longer period, AK-0 has been formulated with ingredients for commercialization, named AK-0 product formulation (AK-0PF). AK-0PF played a role in the suppression of the mycelial growth of the fungicide-resistant pathogen C. gloeosporioides YCHH4 at a greater level than the non-treated control. Moreover, AK-0PF exhibited greater disease suppression of bitter rot in matured under field conditions. Here, we report the complete genome sequence of the AK-0 strain, which has a 3,969,429 bp circular chromosome with 3808 genes and a G+C content of 46.5%. The genome sequence of AK-0 provides a greater understanding of the Bacillus species, which displays biocontrol activity via secondary metabolites. The genome has eight potential secondary metabolite biosynthetic clusters, among which, ituD and bacD genes were expressed at a greater level than other genes. This work provides a better understanding of the strain AK-0, as an effective biocontrol agent (BCA) against phytopathogens, including bitter rot in apple.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.